Use of combined technology will allow researchers to more accurately identify and target the COVID-19 virus — ScienceDaily

In a new study published in the journal Journal of Cellular and Molecular Medicine, A team at the Lawson Health Research Institute has discovered unique blood plasma protein patterns that could help develop a more personalized approach to treating severe COVID-19 in critically ill patients.

The proteins under study, called the plasma proteome, are released by cells that often play an important role in the body’s immune response to viruses. The research team examined how they adapt and change to a COVID-19 infection.

Within the scope of the study, blood samples were taken from 30 people in three patient groups at the London Health Sciences Center (LHSC). One group had patients with COVID-19, another group had patients with severe infection but were negative for COVID-19, and the third was a healthy control group. Blood samples were taken on the day of admission to the intensive care unit and again on the third, seventh and tenth days in the hospital.

LHSC Children’s Hospital Critical Care Physician and Western University Schulich Professor. “We collected plasma from these patients and measured over a thousand proteins with great accuracy using new technology that combines immunology and genomics,” says Douglas Fraser. Faculty of Medicine and Dentistry. “With the use of this advanced technology, we were able to better analyze protein patterns and better understand what is happening in COVID-19, especially in critically ill patients.”

The research team found that COVID-19 patients typically show changes in immune suppression pathways that keep the immune system balanced. In critically ill patients, the changes increased. Analyzes of the plasma proteome helped the researchers determine which cells in the body were active and which signaling pathways were activated in the state of disease.

“In-depth analysis of the human plasma proteome helps us capture tissue proteins that can provide us with information about organ integrity during infection,” says Lawson Research Associate Cristiana Iosef. “This is important because it will allow us to search for new blood biomarkers specific to COVID-19 patients.”

Using the latest analytical technology, this research was delivered with the expertise and technologies available through the Child Health Research Institute (CHRI), a program of Lawson.

Lawson Scientist Director Dr. “This study allowed us to understand the progression of disease processes in very sick patients and provided us with clues about the body’s immune system and other systems that respond to severe illness,” says Victor Han. CHRI and Schulich Professor of Medicine and Dentistry. “We hope this information will allow us to identify patients who will become seriously ill and develop new treatments to counter the changes taking place in their bodies.”

Also a scientist at CHRI, Dr. Fraser adds that the team can now examine potential new drug treatments in hopes of improving outcomes for these patients.

The research team’s next steps will be to use this technology to study plasma biomarkers in long-term COVID patients to determine why some develop long-term illness after a COVID-19 infection.

Story Source:

materials provided by Lawson Health Research Institute. Note: Content can be edited for style and length.

Leave a Reply

Your email address will not be published. Required fields are marked *